Scaling Sustainability: A Big Pharma Formula

In this podcast conversation with Pharm Exec, Jim Greffet, VP of sustainability at Eli Lilly, unpacks how environmental, social, and governance (ESG) goals are shaping the organization’s next phase of growth—particularly as demand surges for its GLP-1 products Zepbound and Mounjaro. From access and affordability to supply chain expansion and climate commitments, Greffet shares the importance of embedding long-term thinking into operational strategy, which for Lilly includes the company's quest to reach 30 million patients in resource-limited settings by 2030, among other ESG goals.

Highlights of Greffet's discussion with Michael Christel, MJH Life Sciences Group Managing Editor, include:

• Why Zepbound/the obesity space has made access a defining sustainability issue
• Building future-ready supply chains while cutting emissions and energy use
• Data-driven measures and accountability — “numbers are your friends”
• Sustainability as “sensible business practice,” not distraction from core mission
• And more!